drugset / Trial / NCT00633659

Pilot Study of Hemospan® in Patients With Chronic Critical Limb Ischemia

NCT00633659

Phase 2 Completed 6 enrolled Sangart
RandomizedSingle-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate the effects of Hemospan infusion on vascular reactivity, regional perfusion and oxygenation of ischemic tissue in patients with chronic critical lower limb ischemia.

Timeline

Start
2007-09
Primary completion
2008-06
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Hemospan Protein / enzyme biologic 250 ml
Subject hydroxyethyl starch Other / unclassified 250 ml

Indications